Diamyd Medical AB: Updated results from clinical trial with Diamyd presented today at diabetes conference

STOCKHOLM, Sept. 20, 2022 /PRNewswire/ -- Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of

Related Keywords

Norway ,Sweden ,Stockholm ,Uppsala ,Uppsala Lan ,Norwegian ,Karolinska Institutet ,Ingridk Hals ,Ulf Hannelius ,European Association For The Study Of Diabetes ,Karolinska University Hospital ,University Hospital In Trondheim ,Company European Phase Iib ,Norwegian University Of Science ,Uppsala University Hospital ,Company Certified Adviser ,Latent Autoimmune Diabetes ,European Association ,Phd Ingridk Hals ,Exhibitor Hall ,Norwegian University ,Molecular Medicine ,Olavs Hospital ,University Hospital ,Stockholm County ,Karolinska University ,Autoimmune Diabetes ,European Phase ,Uppsala University ,Diamyd Medical ,Nextcell Pharma ,Nasdaq First North Growth Market ,Diamyd ,Medical ,Pdated ,Results ,Rom ,Linical ,Trial ,Resented ,Oday ,Diabetes ,Conference ,